Uniting Medically Supervised Injecting Centre

Knight Therapeutics Inc. places No. 22 on The Globe and Mail's fourth-annual ranking of Canada's Top Growing Companies

Retrieved on: 
Friday, September 23, 2022

MONTREAL, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (Knight or the Company) is pleased to announce it placed No.

Key Points: 
  • MONTREAL, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (Knight or the Company) is pleased to announce it placed No.
  • 22 on the 2022 Report on Business ranking of Canadas Top Growing Companies.
  • Canadas Top Growing Companies ranks Canadian companies on three-year revenue growth.
  • Canadas Top Growing Companies is an editorial ranking that was launched in 2019.

Knight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in Brazil

Retrieved on: 
Monday, August 15, 2022

MONTREAL, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has assumed full commercial activities and is re-launching Exelon (rivastigmine) in Brazil following successful transfer of the marketing authorization.

Key Points: 
  • MONTREAL, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has assumed full commercial activities and is re-launching Exelon (rivastigmine) in Brazil following successful transfer of the marketing authorization.
  • Exelon is a prescription product that was first approved in 1997 and is currently registered and sold in approximately 90 countries.
  • Exelon is indicated for the symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's disease and Parkinson's disease.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .

Knight to Present at the Canaccord Genuity 42nd Annual Growth Conference

Retrieved on: 
Thursday, August 4, 2022

MONTREAL, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Amal Khouri, Chief Business Officer, is scheduled to present at Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 at 11:00 am ET.

Key Points: 
  • MONTREAL, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Amal Khouri, Chief Business Officer, is scheduled to present at Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 at 11:00 am ET.
  • Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .
  • Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2021 as filed on www.sedar.com .

Notice of Knight Therapeutics' Second Quarter 2022 Results Conference Call

Retrieved on: 
Thursday, August 4, 2022

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.

Key Points: 
  • Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .
  • Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2021 as filed on www.sedar.com .
  • Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information or future events, except as required by law.

Knight Announces Normal Course Issuer Bid

Retrieved on: 
Tuesday, July 12, 2022

MONTREAL, July 12, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company "), a leading pan-American (ex-US) specialty pharmaceutical company, announced today acceptance by the Toronto Stock Exchange (the "TSX") of the Company's Notice of Intention to Make a Normal Course Issuer Bid ("NCIB").

Key Points: 
  • MONTREAL, July 12, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company "), a leading pan-American (ex-US) specialty pharmaceutical company, announced today acceptance by the Toronto Stock Exchange (the "TSX") of the Company's Notice of Intention to Make a Normal Course Issuer Bid ("NCIB").
  • Knight also entered into an automatic share purchase plan with a broker in order to facilitate purchases of its common shares under the NCIB.
  • The price that Knight will pay for Common Shares in open market transactions will be the market price at the time of purchase.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com
    This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries.

Knight Therapeutics announces relaunch of AKYNZEO® in Brazil

Retrieved on: 
Monday, July 4, 2022

MONTREAL, July 04, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., is assuming full commercial activities and is relaunching AKYNZEO (netupitant / palonosetron) in Brazil.

Key Points: 
  • MONTREAL, July 04, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., is assuming full commercial activities and is relaunching AKYNZEO (netupitant / palonosetron) in Brazil.
  • According to IQVIA, sales of AKYNZEO in Canada and Brazil were approximately $7 million in 2021.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .
  • Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2021 as filed on www.sedar.com .

Knight to Present at the 2022 BIO International Convention in San Diego

Retrieved on: 
Tuesday, June 7, 2022

MONTREAL, June 07, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Amal Khouri, Chief Business Officer, is scheduled to present at the 2022 BIO International Convention on Tuesday, June 14, 2022 at 2:45 pm Pacific Time.

Key Points: 
  • MONTREAL, June 07, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Amal Khouri, Chief Business Officer, is scheduled to present at the 2022 BIO International Convention on Tuesday, June 14, 2022 at 2:45 pm Pacific Time.
  • The annual BIO International Convention, hosted by Biotechnology Innovation Organization (BIO), is the worlds largest industry gathering and brings together thousands of global biotechnology and biopharmaceutical leaders.
  • Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .

Knight to Present at the Jefferies 2022 Healthcare Conference in New York City

Retrieved on: 
Friday, June 3, 2022

MONTREAL, June 03, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight") a pan-America (ex-USA) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present at the Jefferies 2022 Healthcare Conference on Friday, June 10, 2022 at 10:00 AM ET in New York City.

Key Points: 
  • MONTREAL, June 03, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight") a pan-America (ex-USA) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present at the Jefferies 2022 Healthcare Conference on Friday, June 10, 2022 at 10:00 AM ET in New York City.
  • Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .
  • Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information or future events, except as required by law.

Knight Therapeutics Assumes Commercial Activities for Exelon in Colombia

Retrieved on: 
Wednesday, June 1, 2022

MONTREAL, June 01, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Colombian affiliate, Biotoscana Farma S.A., is in the process of assuming full commercial activities for Exelon (rivastigmine) in Colombia upon successful transfer of the marketing authorization.

Key Points: 
  • MONTREAL, June 01, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Colombian affiliate, Biotoscana Farma S.A., is in the process of assuming full commercial activities for Exelon (rivastigmine) in Colombia upon successful transfer of the marketing authorization.
  • Exelon is a prescription product that was first approved in 1997 and is currently registered and sold in approximately 90 countries.
  • "We are excited to assume full commercial activities of Exelon in Colombia and continue to support this well established and important therapy option in an area of such high unmet need as Alzheimer's," said Samira Sakhia, President & Chief Executive Officer of Knight.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .

Knight Therapeutics Enters into Exclusive License and Supply Agreements with Rigel Pharmaceuticals to Commercialize Fostamatinib in Latin America

Retrieved on: 
Tuesday, May 24, 2022

MONTREAL, May 24, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD), a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has entered into exclusive license and supply agreements with Rigel Pharmaceuticals granting Knight the rights to commercialize fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in Latin America.

Key Points: 
  • MONTREAL, May 24, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD), a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has entered into exclusive license and supply agreements with Rigel Pharmaceuticals granting Knight the rights to commercialize fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in Latin America.
  • In return, Knight receives exclusive rights to fostamatinib in all potential indications, including chronic ITP, wAIHA, and COVID-19 in Latin America.
  • We are excited to be working with Rigel to provide access to an innovative, first-in-class treatment option to patients across Latin America with chronic ITP.
  • TAVALISSE and TAVLESSE are registered trademarks of Rigel Pharmaceuticals, Inc.
    Investor Contact for Knight Therapeutics Inc.: